Express Pharma highlights the significant amount of H2020 funding that has helped UK Bio/Pharma companies advance their innovative technologies – Stablepharma Ltd received €50,000 to further develop its StablevaX™ technology. Full article can be found here. Through the Brexit deal struck between the UK and EU on 24 December 2021, the UK will be part […]
Read More
As featured in Manufacturing Chemist publication 30th Mar 2021. https://www.manufacturingchemist.com/news/article_page/Stablepharma_and_BB-NCIPD_collaborating_on_thermally_stable_vaccine/175613 The companies are developing a version of BB-NCIPD’s Td vaccine using Stablepharma’s StablevaX technology Stablepharma has announced a collaboration with European vaccine manufacturer BB-NCIPD (Bul Bio), to develop a thermally stable version of the Tetanus diphtheria (Td) vaccine using the patented StablevaX formulation and device. […]
Read More